Medexus Pharmaceuticals Company Executives
| MDP Stock | 2.74 0.07 2.49% |
Medexus Pharmaceuticals employs about 91 people. The company is managed by 10 executives with a total tenure of roughly 213 years, averaging almost 21.0 years of service per executive, having 9.1 employees per reported executive. Analysis of Medexus Pharmaceuticals' management performance can provide insight into the firm performance.
Medexus |
Medexus Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0455 % which means that it generated a profit of $0.0455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0545 %, meaning that it generated $0.0545 on every $100 dollars invested by stockholders. Medexus Pharmaceuticals' management efficiency ratios could be used to measure how well Medexus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of July 2025, Return On Equity is likely to grow to 0.24, while Return On Tangible Assets are likely to drop (1.32). At this time, Medexus Pharmaceuticals' Asset Turnover is very stable compared to the past year.As of the 22nd of July 2025, Net Income Applicable To Common Shares is likely to grow to about 2.4 M, while Common Stock Shares Outstanding is likely to drop about 17.9 M.
Medexus Pharmaceuticals Workforce Comparison
Medexus Pharmaceuticals is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,079. Medexus Pharmaceuticals holds roughly 91.0 in number of employees claiming about 8% of equities under Health Care industry.
Medexus Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.01) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.01.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.64 | 0.5223 |
|
|
Medexus Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medexus Pharmaceuticals Price Series Summation is a cross summation of Medexus Pharmaceuticals price series and its benchmark/peer.
Medexus Pharmaceuticals Notable Stakeholders
A Medexus Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medexus Pharmaceuticals often face trade-offs trying to please all of them. Medexus Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medexus Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Brian Peters | Vice States | Profile | |
| Brendon Bushman | Chief Officer | Profile | |
| Richard Labelle | Chief Officer | Profile | |
| Marcel Konrad | Chief Officer | Profile | |
| Michael Adelman | US Mang | Profile | |
| Ian Brown | General Secretary | Profile | |
| Kenneth dEntremont | CEO Director | Profile | |
| Tina CFA | Executive Relations | Profile | |
| Bill Poncy | Senior States | Profile | |
| Brendon Buschman | Chief Officer | Profile |
About Medexus Pharmaceuticals Management Performance
The success or failure of an entity such as Medexus Pharmaceuticals often depends on how effective the management is. Medexus Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medexus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medexus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.02 | (1.32) | |
| Return On Capital Employed | 0.11 | (0.09) | |
| Return On Assets | 0.01 | (1.32) | |
| Return On Equity | 0.04 | 0.24 |
Medexus Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Medexus Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medexus Pharmaceuticals within its industry.Medexus Pharmaceuticals Manpower Efficiency
Return on Medexus Pharmaceuticals Manpower
| Revenue Per Employee | 1.2M | |
| Revenue Per Executive | 10.8M | |
| Net Income Per Employee | 24.7K | |
| Net Income Per Executive | 224.7K |
Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.